Cargando…
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results
OBJECTIVES: Recently, the results of two economic evaluations were published both of which seemingly demonstrate the cost-effectiveness of sofosbuvir-based regimens for the treatment of chronic hepatitis C genotype 1 infection in Germany. Both analyses were sponsored by the manufacturer of sofosbuvi...
Autor principal: | Gandjour, Afschin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531817/ https://www.ncbi.nlm.nih.gov/pubmed/33006987 http://dx.doi.org/10.1371/journal.pone.0236543 |
Ejemplares similares
-
Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results"
por: Mühlbacher, Axel C., et al.
Publicado: (2021) -
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
por: Gandjour, Afschin
Publicado: (2023) -
How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
por: Gandjour, Afschin
Publicado: (2021) -
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017) -
Costs of patients with chronic kidney disease in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)